DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma

Information source: University of Glasgow
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Asthma

Intervention: Ambrisentan (Drug); Bosentan (Drug); Placebo (Drug)

Phase: Phase 2

Status: Not yet recruiting

Sponsored by: University of Glasgow

Official(s) and/or principal investigator(s):
Mark Spears, MBChB PhD, Principal Investigator, Affiliation: University of Glasgow

Overall contact:
Mark Spears, MBChB PhD, Phone: 0141 211 1673, Email: mark.spears@glasgow.ac.uk


The purpose of this study will be to determine if blockade of endothelin 1 signalling via endothelin receptor A using ambrisentan or dual blockade (A&B) via bosentan can provide protection against methacholine induced bronchoconstriction in asthma.

Clinical Details

Official title: Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Difference in doubling dose of methacholine to produce bronchoconstriction compared to placebo

Secondary outcome: Which of the endothelin receptors A&B are most bronchoprotective against methacholine

Detailed description: Endothelin 1 may have a role in the development of acute airway narrowing in asthma. Blockade of the endothelin system may thereby protect against airway narrowing. Two receptors exist for endothelin 1, Endothelin A & B. Both can be blocked by Bosentan, and the A receptor by ambrisentan. Both medications are currently in use for the treatment of pulmonary arterial hypertension. The investigators will endeavour to examine the potential role of endothelin 1 in the development of airway narrowing in asthma through blockade of the endothelin receptors A&B through the use of bosentan and ambrisentan.


Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.


Inclusion Criteria: 1. Physician diagnosis of asthma confirmed objectively by airway hyperactivity to methacholine (as determined by a ≥ 20% drop in FEV at a methacholine dose of ≤ 8mg/ml after β-agonist withdrawal as per ATS guidelines) 2. Age range 18-60 years 3. FEV1 ≥ 60% predicted 4. Duration of asthma > 6 months and on stable medication for 4 weeks 5. Prescribed and compliant with inhaled corticosteroid up to a maximum of 2000mcg beclomethasone or equivalent 6. No history of previous regular smoking and current non-smoker Exclusion Criteria: 1. Unstable asthma; defined as the presence of 1 or more of the following events in the month prior to study [Emergency/'out of hours' visit to GP for asthma exacerbation; GP visit to patient at home for asthma exacerbation or A & E/hospital admission for asthma exacerbation] 2. Treatment with oral corticosteroids in the past month 3. Need for maintenance oral corticosteroid therapy 4. Pregnancy or planning to become pregnant over course of study and up to one month after 5. Excessive risk of hepatotoxicity from endothelin receptor antagonists;

- Alcohol excess (defined as regular consumption above government daily recommend

limits; currently defined as 28 units per wk for men, 21 units per week for women)

- Previous intravenous drug use

- Current or known history of liver disease (with the exception of Gilberts

disease and gallstones)

- Chronic hepatitis (either viral (e. g. hepatitis B or C) or autoimmune)

- Bilirubin, alanine aminotransferase (ALT) or asparate aminotransferase (AST)

greater than the upper limit of normal at screening 6. Anaemia (defined as haemoglobin below the lower reference range for sex) at screening 7. Renal failure (defined as eGFR less than 50 mL/minute/1. 73 m2) at screening 8. Known HIV positivity 9. History of inability to tolerate bosentan or ambrisentan 10. Significant medical conditions other than asthma felt by investigator to preclude participation in study. This could be either in patients best interest or due to potential to significantly alter responses to medication and hence alter power of clinical trial (examples include; significant heart failure (NYHA grades II-IV), diabetes mellitus, bronchiectasis or haematological malignancy).

Locations and Contacts

Mark Spears, MBChB PhD, Phone: 0141 211 1673, Email: mark.spears@glasgow.ac.uk

Asthma Research Unit, University of Glasgow, Glasgow G12 0YN, United Kingdom; Not yet recruiting
Mark Spears, MD PhD, Phone: 441412111673, Email: mark.spears@glasgow.ac.uk
Rekha Chaudhuri, MD, Phone: 441412111673, Email: rekhachaudhuri@yahoo.com
Mark Spears, MD PhD, Principal Investigator
Rekha Chaudhuri, Sub-Investigator
Neil C Thomson, MD FRCP, Sub-Investigator
Additional Information

Starting date: November 2012
Last updated: June 10, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017